The many pathways driving liver inflammation in MASH - PubMed
6 hours ago
- #inflammation
- #liver disease
- #metabolic disorder
- Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one-third of the global population.
- Up to 20% of MASLD patients develop metabolic dysfunction-associated steatohepatitis (MASH), which can lead to liver cirrhosis and hepatocellular carcinoma.
- MASH development is driven by hepatic lipotoxicity, intestinal dysbiosis, and pro-inflammatory diets affecting immune responses.
- Adipose tissue contributes to systemic inflammation in obesity, worsening MASH.
- Polygenetic and multiomic risk scores help identify distinct types of MASLD with varying disease aggressiveness.
- Current MASH drugs have pleiotropic metabolic and anti-inflammatory effects, promising improved clinical management.